Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600671's EV-to-EBIT is ranked worse than 96.04% of 682
companies
in the Drug Manufacturers industry
Industry Median: 15.985
vs SHSE:600671: 152.77
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hangzhou TianMuShan Pharmaceutical Enterprise Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥2,197.9 Mil.
Hangzhou TianMuShan Pharmaceutical Enterprise Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥18.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou TianMuShan Pharmaceutical Enterprise Co EV-to-EBIT Related Terms
Hangzhou TianMuShan Pharmaceutical Enterprise Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou TianMuShan Pharmaceutical Enterprise Co EV-to-EBIT Chart
Hangzhou TianMuShan Pharmaceutical Enterprise Co Annual Data
SHSE:600671 vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Hangzhou TianMuShan Pharmaceutical Enterprise Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou TianMuShan Pharmaceutical Enterprise Co EV-to-EBIT vs Drug Manufacturers Industry
Hangzhou TianMuShan Pharmaceutical Enterprise Co's current Enterprise Value is ¥2,806.8 Mil.
Hangzhou TianMuShan Pharmaceutical Enterprise Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥18.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) has a EV-to-EBIT of 150.04 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors. This is 566% above median its historical median of 22.52. According to the industry distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #655 out of 682 companies in the Drug Manufacturers industry, placing it in the top 96%.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co's EV-to-EBIT too high?
Hangzhou TianMuShan Pharmaceutical Enterprise Co's current EV-to-EBIT of 150.04 is 566% above median its 10-year median of 22.52. The Drug Manufacturers industry median EV-to-EBIT is 15.99. Hangzhou TianMuShan Pharmaceutical Enterprise Co's value of 150.04 is 838.6% above this industry median. Based on the distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #655 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hangzhou TianMuShan Pharmaceutical Enterprise Co has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou TianMuShan Pharmaceutical Enterprise Co's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Hangzhou TianMuShan Pharmaceutical Enterprise Co ranks #655 out of 682 companies for EV-to-EBIT. This places Hangzhou TianMuShan Pharmaceutical Enterprise Co in the lower half of its industry. The industry median EV-to-EBIT is 15.99. Hangzhou TianMuShan Pharmaceutical Enterprise Co's value of 150.04 is 838.6% above this benchmark. While the company's 10-year median is 22.52 vs. the industry median of 15.99, Hangzhou TianMuShan Pharmaceutical Enterprise Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.99, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current EV-to-EBIT of 150.04 is 838.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hangzhou TianMuShan Pharmaceutical Enterprise Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou TianMuShan Pharmaceutical Enterprise Co's current EV-to-EBIT is 150.04, which is 566% above median its own 10-year median of 22.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥15.03, compared to a current price of ¥21.88 — trading 45.6% above its estimated fair value. The current EV-to-EBIT is 150.04, which is 566% above median its 10-year median of 22.52 and 838.6% above the Drug Manufacturers industry median of 15.99. Hangzhou TianMuShan Pharmaceutical Enterprise Co's overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671), the current EV-to-EBIT is 150.04 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou TianMuShan Pharmaceutical Enterprise Co (SHSE:600671) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou TianMuShan Pharmaceutical Enterprise Co stock appears to be overvalued.
The current stock price of ¥21.88 is trading 45.6% above its estimated GF Value™ of ¥15.03.
GuruFocus considers Hangzhou TianMuShan Pharmaceutical Enterprise Co to be Significantly Overvalued.
Key valuation signals for SHSE:600671:
EV-to-EBIT: 150.04 (566% above median its 10-year median of 22.52)
GF Value™: ¥15.03 vs. price of ¥21.88 (45.6% above fair value)
Industry Position: 838.6% above the Drug Manufacturers median (#655 of 682)
No single metric tells the full story. See the SHSE:600671 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd is engaged in producing proprietary Chinese medicines, biopharmaceuticals, healthy foods, medical equipment, and other medicines in China.
48GF Score
Get the complete analysis for SHSE:600671
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600671 has been successfully added to your 
